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Purpose of the study
HAART efficacy for HIV-infected patients increased over
time as more drugs and novel drug classes became availa-
ble. It is not yet fully clear, however, which factors are
most relevant to the increased success of more recent first-
line regimens. We therefore planned to retrospectively
investigate the efficacy of first-line regimens prescribed at
our Institutions in 1998 and 2006.
Methods
Clinical records of all consecutive patients starting their
first line HAART during 1998 and 2006 were evaluated
for: age, sex, risk factors, co-morbidities, CDC stage, treat-
ment adherence, record of any toxic event and/or therapy
modification, basal, 24- and 48-week CD4 T-cell counts,
HIV viremia, glycaemia, total cholesterol, triglycerides. All
statistical analyses were performed using the Stata 10 soft-
ware.
Summary of results
146 patients were included, 76.0% males, with a mean
age of 38.2 years, mean basal CD4 T-cells 250.3/mm3 and
HIV viremia 5.66 log10 copies/mL; 67 patients were con-
sidered in 1998, 79 in 2006, without any significant dif-
ference for basal values. HIV suppression at 48 weeks was
observed in 59.1% of patients in 1998 and in 88.6% in
2006 (p < 0.001). Multivariate logistic regression demon-
strated that viral suppression was independently associ-
ated only with 48-week adherence (OR 20.6, CI 5.9–71.9,
p < 0.001) and being treated in 2006 (OR 8.6, CI 2.4–
30.6, p < 0.001). Moreover, adherence to HAART was sig-
nificantly associated with better immune recovery at 24
weeks (p = 0.01) and 48 weeks (p = 0.02). Neither demo-
graphic, nor basal immune parameters, nor adverse events
significantly altered the likelihood of viral suppression.
Conclusion
Our results indicate that after 48 weeks, patients treated
with more recent first-line regimens have better chances of
viral suppression and immune recovery than at the dawn
of HAART. Adherence to therapy seems to be increased in
parallel over time, and to be tightly associated with both
outcomes. The independent association of better out-
comes with the year of treatment and not with any other
factor, including the incidence of adverse events, would
suggest greater intrinsic potency of new HAART regimens.
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